{"id":36920,"date":"2026-06-03T19:57:32","date_gmt":"2026-06-03T14:27:32","guid":{"rendered":"https:\/\/atsixty.com\/?p=36920"},"modified":"2026-06-03T19:58:11","modified_gmt":"2026-06-03T14:28:11","slug":"liver-diseases","status":"publish","type":"post","link":"https:\/\/atsixty.com\/index.php\/cms\/liver-diseases\/","title":{"rendered":"Liver Diseases"},"content":{"rendered":"\n\n\n<link href=\"https:\/\/fonts.googleapis.com\/css2?family=Playfair+Display:ital,wght@0,400;0,600;0,700;1,400;1,600&#038;family=Source+Serif+4:ital,wght@0,300;0,400;0,600;1,400&#038;display=swap\" rel=\"stylesheet\">\n<style>\n\/* ============================================================\n   Morning Rounds \u00b7 GIT Quiz 04 \u00b7 Liver Diseases\n   Namespace: #git04\n   Palette: deep teal-green (GIT series standard)\n   Template: git02\/git03 \u2014 plain diff label, exp + Extra Points\n   ============================================================ *\/\n\n#git04 *,#git04 *::before,#git04 *::after{box-sizing:border-box;margin:0;padding:0}\n\n#git04{\n  --ter:#1A6B5A;\n  --ter-light:#2A8C77;\n  --ter-pale:#EBF6F3;\n  --ter-dark:#125048;\n  --correct:#2D6B47;\n  --correct-bg:#EAF6EF;\n  --correct-border:#3A9960;\n  --wrong:#B83232;\n  --wrong-bg:#FDF0F0;\n  --wrong-border:#E53935;\n  --ink:#1C2E2A;\n  --ink-mid:#3D5A54;\n  --ink-soft:#7A9A94;\n  --line:#D8E8E5;\n  --cream:#F5FAF9;\n  --warm:#FDFFFE;\n\n  font-family:'Source Serif 4',Georgia,serif;\n  font-size:16px;color:var(--ink);background:var(--cream);\n  line-height:1.7;padding:0 0 64px;\n}\n\n#git04 .mr-header{background:var(--ter);color:#FDFFFE;padding:34px 24px 28px;text-align:center}\n#git04 .mr-eyebrow{font-size:0.68rem;letter-spacing:0.18em;text-transform:uppercase;font-weight:600;opacity:0.65;margin-bottom:10px}\n#git04 .mr-title{font-family:'Playfair Display',serif;font-size:1.75rem;font-weight:700;line-height:1.2;margin-bottom:4px}\n#git04 .mr-title em{font-style:italic;font-weight:400;opacity:0.88}\n#git04 .mr-subtitle{font-size:0.82rem;opacity:0.7;margin-top:8px;font-style:italic}\n#git04 .mr-chips{display:flex;justify-content:center;gap:10px;margin-top:18px;flex-wrap:wrap}\n#git04 .mr-chip{background:rgba(255,255,255,0.13);border:1px solid rgba(255,255,255,0.22);border-radius:20px;padding:4px 13px;font-size:0.73rem}\n\n#git04 .mr-sentinel{height:1px}\n#git04 .mr-progress{position:fixed;top:0;left:0;right:0;z-index:9999;background:var(--warm);border-bottom:1px solid var(--line);box-shadow:0 2px 12px rgba(26,107,90,0.10);padding:9px 16px;display:none}\n#git04 .mr-progress.visible{display:block}\n#git04 .mr-prog-inner{max-width:720px;margin:0 auto;display:flex;align-items:center;justify-content:center}\n#git04 .mr-pips{display:flex;align-items:center;justify-content:center}\n#git04 .mr-pip-wrap{display:flex;align-items:center}\n#git04 .mr-pip-line{width:28px;height:2px;background:var(--line);transition:background 0.35s}\n#git04 .mr-pip-line.done{background:var(--ter)}\n#git04 .mr-pip{width:28px;height:28px;border-radius:50%;border:2px solid var(--line);background:var(--warm);display:flex;align-items:center;justify-content:center;font-size:0.63rem;font-weight:700;color:var(--ink-soft);transition:all 0.3s;flex-shrink:0}\n#git04 .mr-pip.correct{background:var(--correct-border);border-color:var(--correct-border);color:#fff}\n#git04 .mr-pip.wrong{background:var(--wrong-border);border-color:var(--wrong-border);color:#fff}\n\n#git04 .mr-body{max-width:720px;margin:0 auto;padding:0 16px}\n#git04 .mr-case{background:var(--warm);border:1px solid var(--line);border-left:4px solid var(--ter);border-radius:10px;margin:28px 0;overflow:hidden;box-shadow:0 1px 6px rgba(26,107,90,0.06)}\n#git04 .mr-case-top{padding:16px 20px 14px;display:flex;gap:14px;align-items:flex-start}\n#git04 .mr-num{font-family:'Playfair Display',serif;font-size:2.2rem;font-weight:700;color:var(--ter);opacity:0.16;line-height:1;margin-top:-2px;flex-shrink:0}\n#git04 .mr-meta{flex:1}\n#git04 .mr-tag-row{display:flex;align-items:center;justify-content:space-between;margin-bottom:5px}\n#git04 .mr-tag{font-size:0.61rem;font-weight:700;letter-spacing:0.14em;text-transform:uppercase;color:var(--ter);opacity:0.8}\n#git04 .mr-diff{font-size:0.61rem;font-weight:700;letter-spacing:0.10em;text-transform:uppercase;color:var(--ink-soft)}\n#git04 .mr-stem{font-size:0.94rem;color:var(--ink);line-height:1.72}\n#git04 .mr-stem strong{font-weight:600}\n#git04 .mr-stem em{font-style:italic}\n#git04 .mr-rule{height:1px;background:var(--line);margin:0 20px}\n\n#git04 .mr-opts{padding:12px 20px 16px;display:flex;flex-direction:column;gap:8px}\n#git04 .mr-opt{display:flex;align-items:flex-start;gap:11px;padding:10px 14px;border:1.5px solid var(--line);border-radius:8px;cursor:pointer;background:var(--warm);transition:border-color 0.15s,background 0.15s;-webkit-tap-highlight-color:transparent}\n#git04 .mr-opt:hover{border-color:var(--ter);background:var(--ter-pale)}\n#git04 .mr-opt.locked{cursor:default}\n#git04 .mr-opt.locked:hover{border-color:var(--line);background:var(--warm)}\n#git04 .mr-opt.correct{border-color:var(--correct-border);background:var(--correct-bg);cursor:default}\n#git04 .mr-opt.correct:hover{border-color:var(--correct-border);background:var(--correct-bg)}\n#git04 .mr-opt.wrong{border-color:var(--wrong-border);background:var(--wrong-bg);cursor:default}\n#git04 .mr-opt.wrong:hover{border-color:var(--wrong-border);background:var(--wrong-bg)}\n#git04 .mr-opt.dimmed{opacity:0.35;cursor:default}\n#git04 .mr-opt.dimmed:hover{border-color:var(--line);background:var(--warm)}\n#git04 .mr-ltr{flex-shrink:0;width:20px;height:20px;border-radius:50%;border:1.5px solid var(--line);display:flex;align-items:center;justify-content:center;font-size:0.62rem;font-weight:700;color:var(--ink-soft);margin-top:2px;transition:all 0.15s}\n#git04 .mr-opt.correct .mr-ltr{background:var(--correct-border);border-color:var(--correct-border);color:#fff}\n#git04 .mr-opt.wrong .mr-ltr{background:var(--wrong-border);border-color:var(--wrong-border);color:#fff}\n#git04 .mr-opt-text{font-size:0.9rem;color:var(--ink-mid);line-height:1.58}\n#git04 .mr-opt.correct .mr-opt-text{color:var(--correct);font-weight:600}\n#git04 .mr-opt.wrong .mr-opt-text{color:var(--wrong)}\n\n#git04 .mr-exp{display:none;border-top:1px solid #b8ddd6;background:linear-gradient(180deg,#e8f5f2 0%,#f2faf8 100%);padding:13px 20px 15px}\n#git04 .mr-exp-lbl{font-size:0.61rem;font-weight:700;letter-spacing:0.12em;text-transform:uppercase;color:var(--correct);margin-bottom:6px}\n#git04 .mr-exp-text{font-size:0.86rem;color:#1c4a3a;line-height:1.68}\n#git04 .mr-exp-text strong{font-weight:600}\n#git04 .mr-exp-text em{font-style:italic}\n#git04 .mr-exp-extra{margin-top:11px;padding-top:10px;border-top:1px dashed #9ACCC4;font-size:0.84rem;color:#1c4a3a;line-height:1.66}\n#git04 .mr-exp-extra-lbl{font-size:0.59rem;font-weight:700;letter-spacing:0.12em;text-transform:uppercase;color:var(--ter);margin-bottom:4px;display:block}\n#git04 .mr-exp-extra strong{font-weight:600}\n#git04 .mr-exp-extra em{font-style:italic}\n\n#git04 .mr-submit-wrap{text-align:center;padding:28px 16px 8px}\n#git04 .mr-btn{background:var(--ter);color:#FDFFFE;border:none;border-radius:8px;padding:13px 44px;font-family:'Playfair Display',serif;font-size:1rem;font-weight:700;cursor:pointer;box-shadow:0 2px 8px rgba(26,107,90,0.30)}\n#git04 .mr-btn:hover{background:var(--ter-dark)}\n#git04 .mr-score{display:none;background:var(--warm);border:1px solid var(--line);border-top:4px solid var(--ter);border-radius:10px;margin:24px 0 0;box-shadow:0 2px 12px rgba(26,107,90,0.10);overflow:hidden}\n#git04 .mr-score-in{padding:28px 24px;text-align:center}\n#git04 .mr-score-ey{font-size:0.66rem;letter-spacing:0.14em;text-transform:uppercase;color:var(--ink-soft);margin-bottom:12px;font-weight:600}\n#git04 .mr-ring{width:98px;height:98px;border-radius:50%;background:conic-gradient(var(--ter) 0%,var(--line) 0%);display:flex;align-items:center;justify-content:center;margin:0 auto 16px;position:relative}\n#git04 .mr-ring::before{content:'';position:absolute;width:76px;height:76px;border-radius:50%;background:var(--warm)}\n#git04 .mr-ring-in{position:relative;display:flex;flex-direction:column;align-items:center;line-height:1.2}\n#git04 .mr-ring-pct{font-family:'Playfair Display',serif;font-size:1.3rem;font-weight:700;color:var(--ter)}\n#git04 .mr-ring-sub{font-size:0.54rem;color:var(--ink-soft);text-transform:uppercase;letter-spacing:0.06em}\n#git04 .mr-score-title{font-family:'Playfair Display',serif;font-size:1.15rem;font-weight:700;color:var(--ink);margin-bottom:4px}\n#git04 .mr-score-net{font-size:0.9rem;color:var(--ter);font-weight:600;margin-bottom:4px}\n#git04 .mr-verdict{font-size:0.83rem;color:var(--ink-soft);font-style:italic;margin-bottom:18px;padding:0 12px}\n#git04 .mr-bands{display:flex;justify-content:center;gap:10px;flex-wrap:wrap}\n#git04 .mr-band{padding:5px 13px;border-radius:16px;font-size:0.78rem;font-weight:600}\n#git04 .mr-band-c{background:var(--correct-bg);color:var(--correct)}\n#git04 .mr-band-w{background:var(--wrong-bg);color:var(--wrong)}\n#git04 .mr-band-s{background:var(--ter-pale);color:var(--ter)}\n#git04 .mr-retry{display:block;margin:18px auto 4px;background:transparent;border:2px solid var(--ter);color:var(--ter);border-radius:8px;padding:9px 28px;font-family:'Playfair Display',serif;font-size:0.92rem;font-weight:700;cursor:pointer}\n#git04 .mr-retry:hover{background:var(--ter);color:#FDFFFE}\n\n@media(max-width:480px){\n  #git04 .mr-title{font-size:1.4rem}\n  #git04 .mr-num{font-size:1.7rem}\n  #git04 .mr-stem{font-size:0.9rem}\n  #git04 .mr-opt-text{font-size:0.86rem}\n}\n<\/style>\n\n<div id=\"git04\">\n\n  <div class=\"mr-header\">\n    <div class=\"mr-eyebrow\">Morning Rounds &middot; GIT Series<\/div>\n    <div class=\"mr-title\">\n      Liver Diseases<br><em>Gastroenterology<\/em>\n    <\/div>\n    <div class=\"mr-subtitle\">Five high-yield clinical cases &middot; +4 \/ &minus;1 scoring &middot; NEET-PG and UPSC CMS<\/div>\n    <div class=\"mr-chips\">\n      <span class=\"mr-chip\">5 Cases<\/span>\n      <span class=\"mr-chip\">+4 \/ &minus;1 scoring<\/span>\n      <span class=\"mr-chip\">Options reshuffled<\/span>\n    <\/div>\n  <\/div>\n\n  <div class=\"mr-sentinel\" id=\"git04-sentinel\"><\/div>\n\n  <div class=\"mr-progress\" id=\"git04-progress\">\n    <div class=\"mr-prog-inner\">\n      <div class=\"mr-pips\" id=\"git04-pips\"><\/div>\n    <\/div>\n  <\/div>\n\n  <div class=\"mr-body\">\n    <div id=\"git04-cases\"><\/div>\n    <div class=\"mr-submit-wrap\">\n      <button class=\"mr-btn\" id=\"git04-submit\">Submit for Debrief<\/button>\n    <\/div>\n    <div class=\"mr-score\" id=\"git04-score\">\n      <div class=\"mr-score-in\">\n        <div class=\"mr-score-ey\">Round Complete<\/div>\n        <div class=\"mr-ring\" id=\"git04-ring\">\n          <div class=\"mr-ring-in\">\n            <span class=\"mr-ring-pct\" id=\"git04-pct\">0%<\/span>\n            <span class=\"mr-ring-sub\">net<\/span>\n          <\/div>\n        <\/div>\n        <div class=\"mr-score-title\">Your Debrief<\/div>\n        <div class=\"mr-score-net\" id=\"git04-net\"><\/div>\n        <div class=\"mr-verdict\" id=\"git04-verdict\"><\/div>\n        <div class=\"mr-bands\">\n          <span class=\"mr-band mr-band-c\" id=\"git04-ct-c\"><\/span>\n          <span class=\"mr-band mr-band-w\" id=\"git04-ct-w\"><\/span>\n          <span class=\"mr-band mr-band-s\" id=\"git04-ct-s\"><\/span>\n        <\/div>\n        <button class=\"mr-retry\" id=\"git04-retry\">&#8635; New Round<\/button>\n      <\/div>\n    <\/div>\n  <\/div>\n<\/div>\n\n<script>\n\/* ============================================================\n   Morning Rounds \u00b7 GIT Quiz 04 \u00b7 Liver Diseases\n   Namespace : git04\n   TOTAL     : 5 questions  |  MAX : 20  |  +4 \/ \u22121\n   Shuffle   : Fisher-Yates on options each build()\n   Correct   : matched by answer TEXT\n   Debrief   : q.exp = main text; q.extra = Extra Points para\n   ============================================================ *\/\n(function () {\n  'use strict';\n\n  var NS    = 'git04';\n  var TOTAL = 5;\n  var MAX   = 20;\n  var LTRS  = ['A','B','C','D'];\n\n  \/* ================================================================\n     QUESTION BANK \u2014 Liver Diseases\n     Topics: Alcoholic liver disease, NAFLD\/NASH,\n             Cirrhosis & portal hypertension,\n             Wilson's disease, Hepatic encephalopathy\n\n     Q1  ALCOHOLIC LIVER DISEASE \u2014 SPECTRUM & AST:ALT RATIO (Easy)\n         Spectrum: fatty liver (steatosis) \u2192 alcoholic hepatitis\n           \u2192 cirrhosis.\n         Fatty liver: reversible with abstinence; no symptoms.\n         Alcoholic hepatitis: fever, jaundice, tender\n           hepatomegaly, leukocytosis, elevated bilirubin.\n           Maddrey's Discriminant Function (MDF):\n           MDF = 4.6 \u00d7 (PT patient \u2212 PT control) + bilirubin(mg\/dL)\n           MDF \u2265 32 = severe \u2192 prednisolone (if no infection\/GIB).\n           Contraindicated: active infection, GI bleeding, renal\n           failure \u2014 then use pentoxifylline (controversial now).\n         Key LFT pattern: AST:ALT ratio > 2:1\n           (both rarely exceed 300 IU\/L in alcoholic hepatitis \u2014\n           unlike viral hepatitis where values can be >1000).\n         GGT: elevated; most sensitive marker of alcohol use.\n         Cirrhosis: irreversible; spider naevi, palmar erythema,\n           gynaecomastia, leukonychia, parotid enlargement.\n         Answer: AST:ALT >2:1; MDF \u226532 = severe; GGT most\n                 sensitive; prednisolone for severe AH.\n\n     Q2  NAFLD \/ NASH \u2014 METABOLIC SYNDROME LINK (Easy-Medium)\n         NAFLD: hepatic steatosis (>5% of hepatocytes) without\n           significant alcohol use (<20g\/day women, <30g\/day men)\n           and without other secondary causes.\n         Spectrum: simple steatosis (benign) \u2192 NASH (steatosis +\n           inflammation + ballooning \u00b1 fibrosis) \u2192 cirrhosis \u2192 HCC.\n         Associations: obesity, T2DM, dyslipidaemia,\n           hypertension \u2014 i.e., metabolic syndrome.\n         India: increasingly common; lean NAFLD (normal BMI)\n           occurs more in Indians \u2014 visceral adiposity.\n         Diagnosis: USS liver (first-line, non-invasive);\n           liver biopsy gold standard for NASH vs steatosis.\n         FibroScan (transient elastography): non-invasive\n           fibrosis assessment.\n         Treatment: weight loss (mainstay \u2014 7\u201310% body weight\n           loss improves histology); treat metabolic risk factors;\n           no approved drug yet (semaglutide \/ resmetirom emerging).\n         Answer: Metabolic syndrome association; biopsy gold\n                 standard for NASH; weight loss is treatment.\n\n     Q3  CIRRHOSIS \u2014 PORTAL HYPERTENSION &#038; COMPLICATIONS (Medium)\n         Portal hypertension: portal pressure >12 mmHg\n           (normal 5\u201310 mmHg); clinically significant >12 mmHg.\n         Causes: pre-hepatic (portal vein thrombosis),\n           intrahepatic (cirrhosis \u2014 commonest in India),\n           post-hepatic (Budd-Chiari, cardiac).\n         Complications of portal HTN:\n           Varices: oesophageal (most common bleeding site) and\n             gastric; variceal bleed: terlipressin + endoscopic\n             band ligation (EBL); prophylaxis: propranolol.\n           Ascites: transudate; SAAG \u22651.1 g\/dL = portal HTN;\n             first-line Rx: salt restriction + spironolactone\n             \u00b1 furosemide; large-volume paracentesis (LVP) + albumin.\n           SBP (spontaneous bacterial peritonitis): PMN >250\/mm\u00b3\n             in ascitic fluid; organism = E. coli (#1);\n             treat: cefotaxime IV; prophylaxis: norfloxacin.\n           Hepatorenal syndrome (HRS): functional renal failure\n             in cirrhosis; Rx: terlipressin + albumin.\n           Hepatic encephalopathy: see Q5.\n         TIPS (transjugular intrahepatic portosystemic shunt):\n           for refractory ascites \/ recurrent variceal bleeding.\n         Answer: SAAG \u22651.1 = portal HTN; SBP = PMN >250 +\n                 cefotaxime; variceal bleed = terlipressin + EBL.\n\n     Q4  WILSON'S DISEASE \u2014 COPPER METABOLISM & DIAGNOSIS (Medium)\n         Autosomal recessive; ATP7B gene (chromosome 13);\n           defective hepatic copper excretion into bile.\n         Copper accumulates: liver, brain, cornea, kidneys,\n           RBCs (haemolysis).\n         Age: typically presents 5\u201335 years.\n         Presentations:\n           Liver: chronic hepatitis, cirrhosis, FHF (young patient\n             + FHF + haemolytic anaemia = think Wilson's).\n           Neuropsychiatric: tremor, dysarthria, dysphagia,\n             personality change, psychiatric symptoms (often\n             first presentation in young adults).\n           Kayser-Fleischer rings: golden-brown ring at corneal\n             periphery (Descemet's membrane); seen by slit-lamp;\n             present in >95% with neurological Wilson's, but may\n             be absent in hepatic-only presentation.\n         Investigations:\n           Serum ceruloplasmin: low (<20 mg\/dL) in most.\n           Serum copper: low (paradox \u2014 free copper HIGH, total\n             low because ceruloplasmin-bound fraction low).\n           24-hr urinary copper: elevated (>100 \u00b5g\/day);\n             best screening test.\n           Liver biopsy + copper quantification: gold standard.\n         Treatment: D-penicillamine (first-line, copper chelator);\n           trientine (if penicillamine intolerant);\n           zinc (maintenance \/ presymptomatic).\n         Answer: ATP7B mutation; KF rings; low ceruloplasmin;\n                 high 24-hr urinary copper; D-penicillamine.\n\n     Q5  HEPATIC ENCEPHALOPATHY \u2014 PRECIPITANTS & MANAGEMENT (Hard)\n         Pathogenesis: gut-derived toxins (ammonia chief among\n           them) bypass liver (portosystemic shunting) or are\n           inadequately cleared \u2192 cerebral dysfunction.\n         Grades (West Haven):\n           I: altered sleep, mild confusion\n           II: disorientation, asterixis (flapping tremor)\n           III: stupor, responds to stimuli\n           IV: coma\n         Asterixis (flapping tremor): metabolic encephalopathy;\n           not specific to liver \u2014 also in uraemia, CO2 retention.\n         Precipitants (AEIOU mnemonic adapted):\n           GI bleeding (#1 precipitant \u2014 protein load from blood)\n           Infection \/ SBP\n           Constipation\n           Electrolyte disturbance (hyponatraemia, hypokalaemia)\n           Sedatives \/ opioids \/ benzodiazepines\n           High protein diet\n           Dehydration (diuretic excess)\n           TIPS procedure\n         Management:\n           Treat precipitant (most important step).\n           Lactulose: reduces ammonia by acidifying colon\n             (NH3 \u2192 NH4+, trapped and excreted); first-line.\n           Rifaximin: non-absorbable antibiotic; reduces\n             ammonia-producing gut bacteria; add-on to lactulose.\n           Dietary protein: DO NOT restrict protein long-term\n             (worsens sarcopenia); BCAA preferred.\n           Avoid sedatives and opioids.\n         Answer: GI bleed is #1 precipitant; lactulose first-line;\n                 rifaximin add-on; do not restrict protein.\n     ================================================================ *\/\n\n  var QS = [\n\n    \/* ---- Q1 : Alcoholic Liver Disease ---- *\/\n    {\n      id:      1,\n      diff:    'Easy',\n      tag:     'Liver &mdash; Alcoholic Liver Disease',\n      stem:    'A <strong>48-year-old man<\/strong> with a 20-year history of heavy alcohol use presents with <strong>fever, jaundice, and tender hepatomegaly<\/strong>. His AST is 220 IU\/L and ALT is 95 IU\/L. Prothrombin time is prolonged and serum bilirubin is 14 mg\/dL. His Maddrey\\'s Discriminant Function is calculated at 38. Which statement correctly identifies the <strong>characteristic LFT pattern<\/strong>, the significance of his Maddrey score, and the appropriate treatment?',\n      correct: 'AST:ALT ratio >2:1 is characteristic of alcoholic hepatitis; Maddrey score \u226532 indicates severe disease with high short-term mortality; prednisolone is indicated if there is no active infection or gastrointestinal bleeding',\n      opts: [\n        'AST:ALT ratio >2:1 is characteristic of alcoholic hepatitis; Maddrey score \u226532 indicates severe disease with high short-term mortality; prednisolone is indicated if there is no active infection or gastrointestinal bleeding',\n        'ALT:AST ratio >2:1 is the hallmark of alcoholic hepatitis, distinguishing it from NAFLD; Maddrey score \u226532 indicates mild disease requiring only abstinence and nutritional support',\n        'Transaminases exceeding 1000 IU\/L with AST:ALT >2:1 are required to diagnose alcoholic hepatitis; Maddrey score \u226532 mandates immediate liver transplantation listing',\n        'GGT elevation alone is sufficient to confirm alcoholic hepatitis; Maddrey score is used to assess severity of viral hepatitis, not alcoholic liver disease'\n      ],\n      exp: '<strong>Alcoholic hepatitis<\/strong> has a characteristic LFT pattern: <strong>AST:ALT ratio &gt;2:1<\/strong> (and usually &gt;2:1, often approaching 3:1), with both values rarely exceeding 300 IU\/L \u2014 this ceiling is an important distinguishing feature from viral hepatitis, where transaminases can exceed 1000 IU\/L. The ratio reflects mitochondrial injury (AST is mitochondria-rich) and alcohol-induced depletion of pyridoxal phosphate (ALT requires more cofactor). <strong>GGT<\/strong> is the most sensitive marker of alcohol use and is disproportionately elevated. <strong>Maddrey\\'s Discriminant Function (MDF)<\/strong> = 4.6 \u00d7 (PT<sub>patient<\/sub> \u2212 PT<sub>control<\/sub>) + serum bilirubin (mg\/dL). <strong>MDF \u2265 32 = severe alcoholic hepatitis<\/strong> \u2014 1-month mortality ~35\u201350% without treatment. Indication for <strong>prednisolone 40 mg\/day \u00d7 28 days<\/strong>, provided there is no active infection, active GI bleeding, or renal failure. The Lille score at day 7 assesses response; non-responders have poor prognosis.',\n      extra: '<strong>Spectrum of alcoholic liver disease:<\/strong> Fatty liver (steatosis) \u2192 reversible with abstinence, no specific treatment needed. Alcoholic hepatitis \u2192 acute-on-chronic, significant mortality. Cirrhosis \u2192 irreversible; clinical features include spider naevi, palmar erythema, gynaecomastia, leukonychia (white nails), parotid enlargement, Dupuytren\\'s contracture, and testicular atrophy. <strong>CMS point:<\/strong> The district physician will encounter alcoholic liver disease frequently \u2014 the key clinical decisions are: (1) recognise severe AH using MDF, (2) exclude contraindications before steroids, (3) manage complications (variceal bleed, SBP, HE) as priority over aetiology. Abstinence remains the single most important long-term intervention at all stages.'\n    },\n\n    \/* ---- Q2 : NAFLD \/ NASH ---- *\/\n    {\n      id:      2,\n      diff:    'Easy',\n      tag:     'Liver &mdash; NAFLD \/ NASH',\n      stem:    'A <strong>42-year-old woman<\/strong> with <strong>type 2 diabetes and obesity (BMI 31)<\/strong> is found to have <strong>mildly elevated transaminases<\/strong> (AST 68, ALT 82 IU\/L) on routine check-up. She drinks no alcohol. Ultrasound shows a <strong>bright, echogenic liver<\/strong> consistent with hepatic steatosis. She has no jaundice, no stigmata of chronic liver disease. Which statement correctly identifies the gold standard investigation to distinguish simple steatosis from steatohepatitis, and the most effective treatment?',\n      correct: 'Liver biopsy is the gold standard to distinguish simple steatosis from NASH (steatosis + hepatocyte ballooning + lobular inflammation \u00b1 fibrosis); sustained weight loss of 7\u201310% body weight is the most effective treatment and can improve or reverse histological changes',\n      opts: [\n        'Liver biopsy is the gold standard to distinguish simple steatosis from NASH (steatosis + hepatocyte ballooning + lobular inflammation \u00b1 fibrosis); sustained weight loss of 7\u201310% body weight is the most effective treatment and can improve or reverse histological changes',\n        'Serum ALT level is the gold standard \u2014 ALT >3\u00d7 upper limit of normal confirms NASH; ursodeoxycholic acid (UDCA) is the first-line approved pharmacotherapy for NASH',\n        'FibroScan (transient elastography) is the gold standard for distinguishing steatosis from NASH; metformin directly improves hepatic histology in NASH and is recommended as first-line therapy',\n        'Ultrasound echogenicity scoring is the gold standard for NASH diagnosis; statin therapy is contraindicated in NAFLD due to hepatotoxicity risk and should be stopped immediately'\n      ],\n      exp: '<strong>NAFLD (Non-Alcoholic Fatty Liver Disease)<\/strong> is hepatic steatosis (&gt;5% of hepatocytes) in the absence of significant alcohol use and other secondary causes (drugs, viral hepatitis, Wilson\\'s). <strong>Spectrum:<\/strong> simple steatosis (benign, non-progressive in most) \u2192 <strong>NASH<\/strong> (Non-Alcoholic SteatoHepatitis: steatosis + hepatocyte ballooning + lobular inflammation \u00b1 fibrosis) \u2192 cirrhosis \u2192 HCC. <strong>Diagnosis:<\/strong> Ultrasound is the first-line non-invasive test (bright\/echogenic liver). <strong>Liver biopsy<\/strong> remains the gold standard to confirm NASH and stage fibrosis \u2014 no blood test or imaging can reliably distinguish steatosis from NASH. FibroScan assesses fibrosis stage non-invasively but cannot diagnose NASH. <strong>Treatment:<\/strong> No approved pharmacotherapy yet (as of recent guidelines). <strong>Weight loss of 7\u201310% body weight<\/strong> is the only intervention proven to improve histology, including fibrosis. Control of metabolic risk factors (diabetes, dyslipidaemia, hypertension) is essential.',\n      extra: '<strong>India-specific:<\/strong> <em>Lean NAFLD<\/em> \u2014 NAFLD in individuals with normal BMI \u2014 is disproportionately common among Indians due to greater visceral adiposity at lower BMI thresholds. Standard BMI cut-offs for obesity (30 kg\/m\u00b2) may underestimate metabolic risk in South Asians; Indian guidelines use BMI &gt;23 kg\/m\u00b2 as overweight. <strong>Statins in NAFLD:<\/strong> a common clinical misconception \u2014 statins are <em>not<\/em> contraindicated in NAFLD. Transaminase elevation in NAFLD is not a barrier to statin use; in fact, statins may have a hepatoprotective effect in NAFLD. Stopping statins in a dyslipidaemic NAFLD patient increases cardiovascular risk without benefiting the liver. <strong>CMS relevance:<\/strong> NAFLD is the most common liver disease globally and is rapidly rising in India alongside the T2DM and obesity epidemic \u2014 a district physician will manage this condition far more often than rare metabolic liver diseases.'\n    },\n\n    \/* ---- Q3 : Cirrhosis & Portal Hypertension ---- *\/\n    {\n      id:      3,\n      diff:    'Medium',\n      tag:     'Liver &mdash; Cirrhosis &amp; Portal Hypertension',\n      stem:    'A <strong>55-year-old man with known cirrhosis<\/strong> is admitted with <strong>sudden haematemesis<\/strong>. He is stabilised with IV terlipressin. Upper GI endoscopy confirms <strong>bleeding oesophageal varices<\/strong> and band ligation is performed. Three days later, he develops <strong>fever, abdominal pain, and worsening encephalopathy<\/strong>. Ascitic tap shows <strong>PMN count of 380 cells\/mm\u00b3<\/strong> with no organism on Gram stain. The diagnosis, the first-line antibiotic, and the SAAG value expected in this patient\\'s ascites are:',\n      correct: 'Spontaneous bacterial peritonitis (SBP); first-line treatment is cefotaxime IV; SAAG \u22651.1 g\/dL confirms portal hypertension as the cause of ascites',\n      opts: [\n        'Spontaneous bacterial peritonitis (SBP); first-line treatment is cefotaxime IV; SAAG \u22651.1 g\/dL confirms portal hypertension as the cause of ascites',\n        'Secondary bacterial peritonitis from bowel perforation; first-line treatment is metronidazole + ciprofloxacin; SAAG <1.1 g\/dL indicates an exudative cause consistent with peritonitis',\n        'Spontaneous bacterial peritonitis; first-line treatment is oral norfloxacin as it achieves equivalent ascitic fluid levels to IV antibiotics; SAAG measurement is not useful in cirrhotic ascites',\n        'Tuberculous peritonitis mimicking SBP; ascitic fluid PMN >250 confirms TB peritonitis; anti-tubercular therapy should be started immediately without waiting for culture results'\n      ],\n      exp: '<strong>Spontaneous bacterial peritonitis (SBP)<\/strong> is defined as ascitic fluid <strong>PMN (polymorphonuclear neutrophil) count &gt;250 cells\/mm\u00b3<\/strong> in the absence of a surgically treatable intra-abdominal source of infection. Gram stain and culture are often negative \u2014 the diagnosis is made on cell count alone, and treatment must not be delayed waiting for culture results. <strong>Most common organism:<\/strong> <em>E. coli<\/em> (Gram-negative), followed by <em>Klebsiella<\/em> and Streptococcal species. <strong>Treatment:<\/strong> <strong>Cefotaxime IV<\/strong> (third-generation cephalosporin) \u00d7 5 days \u2014 drug of choice. Add <strong>IV albumin<\/strong> (1.5 g\/kg on day 1, 1 g\/kg on day 3) to prevent hepatorenal syndrome (reduces mortality significantly). <strong>SAAG (Serum-Ascites Albumin Gradient)<\/strong> = serum albumin \u2212 ascitic fluid albumin. <strong>SAAG \u22651.1 g\/dL<\/strong> = portal hypertension cause (cirrhosis, cardiac, Budd-Chiari). SAAG &lt;1.1 = non-portal cause (TB peritonitis, malignancy, pancreatitis).',\n      extra: '<strong>SBP prophylaxis<\/strong> \u2014 high-yield for exams and practice: (1) <em>Primary prophylaxis:<\/em> norfloxacin 400 mg\/day in cirrhotic patients with ascitic protein &lt;1.5 g\/dL + renal impairment or Child-Pugh C. (2) <em>Secondary prophylaxis:<\/em> norfloxacin indefinitely after first SBP episode \u2014 recurrence rate without prophylaxis is ~70% at 1 year. (3) <em>Peri-variceal bleed:<\/em> IV ceftriaxone \u00d7 7 days reduces SBP and mortality in acute variceal haemorrhage \u2014 antibiotics are standard of care in every variceal bleed. <strong>Variceal bleed management summary:<\/strong> terlipressin (vasopressin analogue, reduces portal pressure) + endoscopic band ligation + prophylactic antibiotics + IV albumin. Non-selective beta-blockers (propranolol\/carvedilol) are the pharmacological primary and secondary prophylaxis for varices.'\n    },\n\n    \/* ---- Q4 : Wilson's Disease ---- *\/\n    {\n      id:      4,\n      diff:    'Medium',\n      tag:     'Liver &mdash; Wilson\\'s Disease',\n      stem:    'A <strong>19-year-old man<\/strong> presents with a <strong>3-month history of tremor, slurred speech, and behavioural change<\/strong>. His parents report he was treated for jaundice at age 14 that resolved spontaneously. Examination reveals <strong>golden-brown rings at the periphery of both corneas<\/strong> on slit-lamp examination, and <strong>mild splenomegaly<\/strong>. Serum ceruloplasmin is 12 mg\/dL (normal 20\u201360). The gene involved, the single best screening investigation, and the first-line treatment are:',\n      correct: 'ATP7B gene mutation (chromosome 13); 24-hour urinary copper excretion >100 \u00b5g\/day is the best screening test; D-penicillamine is the first-line copper chelating agent',\n      opts: [\n        'ATP7B gene mutation (chromosome 13); 24-hour urinary copper excretion >100 \u00b5g\/day is the best screening test; D-penicillamine is the first-line copper chelating agent',\n        'ATP7A gene mutation (chromosome X); serum copper level >200 \u00b5g\/dL is the gold standard screening test; zinc acetate is first-line for all presentations including neurological disease',\n        'HEXA gene mutation (chromosome 15); serum ceruloplasmin <20 mg\/dL alone is diagnostic of Wilson\\'s disease; trientine is the only effective chelating agent',\n        'HFE gene mutation (chromosome 6); liver biopsy with Perl\\'s Prussian blue staining for copper quantification is the screening test; desferrioxamine chelates the accumulated copper'\n      ],\n      exp: '<strong>Wilson\\'s disease<\/strong> is an autosomal recessive disorder caused by mutations in the <strong>ATP7B gene (chromosome 13)<\/strong>, encoding a copper-transporting ATPase. Defective biliary copper excretion leads to progressive copper accumulation in the liver, brain, cornea, kidneys, and red blood cells. <strong>Kayser-Fleischer (KF) rings<\/strong> \u2014 golden-brown deposits of copper in Descemet\\'s membrane of the cornea \u2014 are pathognomonic when present; visible on slit-lamp examination. They are present in &gt;95% of patients with neurological Wilson\\'s but may be absent in pure hepatic presentations. <strong>Investigation strategy:<\/strong> Serum ceruloplasmin is low in ~85% (but can be normal in acute hepatic presentations); serum copper is paradoxically low (most copper is ceruloplasmin-bound; free copper is high but total is low). <strong>24-hour urinary copper &gt;100 \u00b5g\/day<\/strong> is the best single screening test \u2014 elevated in symptomatic disease. Liver biopsy with copper quantification (&gt;250 \u00b5g\/g dry weight) is the gold standard.',\n      extra: '<strong>Treatment:<\/strong> <strong>D-penicillamine<\/strong> \u2014 first-line copper chelator; promotes urinary copper excretion; side effects include proteinuria, thrombocytopaenia, SLE-like syndrome, and paradoxical neurological worsening at initiation (due to copper mobilisation). <strong>Trientine<\/strong> \u2014 alternative chelator for those intolerant of penicillamine; fewer side effects. <strong>Zinc<\/strong> \u2014 blocks intestinal copper absorption; used for maintenance therapy and in presymptomatic siblings identified on family screening. <strong>Liver transplantation<\/strong> is curative for hepatic Wilson\\'s (corrects the metabolic defect) \u2014 indicated for FHF or decompensated cirrhosis not responding to chelation. <strong>Key exam trap:<\/strong> Wilson\\'s disease should be considered in <em>any young patient<\/em> with unexplained liver disease, haemolytic anaemia (Coombs-negative), or neuropsychiatric symptoms \u2014 the age range (5\u201335 years) and treatability make it a diagnosis that must not be missed.'\n    },\n\n    \/* ---- Q5 : Hepatic Encephalopathy ---- *\/\n    {\n      id:      5,\n      diff:    'Hard',\n      tag:     'Liver &mdash; Hepatic Encephalopathy',\n      stem:    'A <strong>60-year-old man with Child-Pugh C cirrhosis<\/strong> is brought in with <strong>confusion and inappropriate behaviour<\/strong> since the previous evening. He had a <strong>large upper GI bleed one week ago<\/strong> treated with band ligation. He is on spironolactone and furosemide. Examination shows <strong>asterixis, jaundice, and tense ascites<\/strong>. Serum sodium is 126 mEq\/L and serum potassium is 2.9 mEq\/L. Which single factor is the most likely precipitant of his encephalopathy, and what is the correct sequence of management priorities?',\n      correct: 'GI bleeding is the most likely precipitant (nitrogenous load from intraluminal blood); management: identify and correct precipitant first, then lactulose (first-line ammonia reduction), rifaximin as add-on, correct electrolyte disturbances; do not restrict dietary protein long-term',\n      opts: [\n        'GI bleeding is the most likely precipitant (nitrogenous load from intraluminal blood); management: identify and correct precipitant first, then lactulose (first-line ammonia reduction), rifaximin as add-on, correct electrolyte disturbances; do not restrict dietary protein long-term',\n        'Hyponatraemia is the primary precipitant; management requires immediate hypertonic saline infusion followed by protein restriction to 20 g\/day to reduce ammonia production; lactulose is contraindicated as it worsens electrolyte disturbances',\n        'Furosemide-induced hypokalaemia is the only precipitant; management requires potassium replacement only; rifaximin monotherapy is superior to lactulose and should be used as first-line',\n        'Spontaneous bacterial peritonitis is the precipitant; management requires cefotaxime IV followed by neomycin enemas to sterilise the gut; dietary protein should be eliminated entirely during acute encephalopathy'\n      ],\n      exp: '<strong>Hepatic encephalopathy (HE)<\/strong> results from the accumulation of gut-derived neurotoxins \u2014 principally <strong>ammonia<\/strong> \u2014 that bypass hepatic clearance via portosystemic shunting or inadequate hepatocellular function, leading to astrocyte swelling and neuronal dysfunction. <strong>West Haven grading:<\/strong> Grade I (sleep disturbance, mild confusion) \u2192 Grade II (disorientation, <strong>asterixis<\/strong>) \u2192 Grade III (stupor, responsive to stimuli) \u2192 Grade IV (coma). <strong>Identifying the precipitant is the single most important first step.<\/strong> In this patient, the recent <strong>GI bleed<\/strong> is the most likely cause \u2014 blood in the gut provides an enormous nitrogenous protein load, dramatically increasing ammonia production. Other precipitants: infection\/SBP, constipation, diuretic excess (dehydration\/electrolyte disturbance), benzodiazepines\/opioids, high protein diet, TIPS procedure. <strong>Management:<\/strong> Treat precipitant \u2192 <strong>Lactulose<\/strong> (titrate to 2\u20133 soft stools\/day; acidifies colon, trapping NH\u2083 as NH\u2084\u207a) \u2192 <strong>Rifaximin<\/strong> 550 mg BD (non-absorbable antibiotic; reduces ammonia-producing bacteria; add-on to lactulose for secondary prevention).',\n      extra: '<strong>Protein restriction is a harmful myth:<\/strong> Older guidelines recommended protein restriction in HE \u2014 this is now <em>firmly contraindicated<\/em> as standard practice. Cirrhotic patients are already sarcopenic; protein restriction worsens muscle wasting, which itself worsens HE (muscle is a major alternative site of ammonia metabolism). The current recommendation is <strong>1.2\u20131.5 g\/kg\/day protein<\/strong>, preferring <em>branched-chain amino acids (BCAAs)<\/em> and vegetable\/dairy protein over red meat. <strong>Asterixis<\/strong> (flapping tremor of outstretched hands) is a sign of metabolic encephalopathy \u2014 seen in hepatic, uraemic, and hypercapnic (CO\u2082 retention) encephalopathy. Its absence does not exclude HE, and its presence in a cirrhotic patient with any acute deterioration should trigger a search for the precipitant before attributing it to baseline disease.'\n    }\n\n  ];\n  \/* ================================================================\n     END OF CONTENT \u2014 engine logic below, do not edit\n     ================================================================ *\/\n\n  var answers  = {};\n  var answered = 0;\n  var shuffled = {};\n  var done     = false;\n\n  function byId(id) { return document.getElementById(id); }\n  function gid(sfx) { return byId(NS + '-' + sfx); }\n\n  function shuffleArr(arr) {\n    var a = arr.slice(), i, j, t;\n    for (i = a.length - 1; i > 0; i--) {\n      j = Math.floor(Math.random() * (i + 1));\n      t = a[i]; a[i] = a[j]; a[j] = t;\n    }\n    return a;\n  }\n\n  function countVal(val) {\n    var k, n = 0;\n    for (k in answers) {\n      if (answers.hasOwnProperty(k) && answers[k] === val) n++;\n    }\n    return n;\n  }\n\n  function buildPips() {\n    var cont = gid('pips'), i, q, wl, wp, line, pip;\n    if (!cont) return;\n    cont.innerHTML = '';\n    for (i = 0; i < QS.length; i++) {\n      q = QS[i];\n      if (i > 0) {\n        wl = document.createElement('div'); wl.className = 'mr-pip-wrap';\n        line = document.createElement('div'); line.className = 'mr-pip-line';\n        line.id = NS + '-pl' + q.id;\n        wl.appendChild(line); cont.appendChild(wl);\n      }\n      wp  = document.createElement('div'); wp.className = 'mr-pip-wrap';\n      pip = document.createElement('div'); pip.className = 'mr-pip';\n      pip.id = NS + '-pip' + q.id;\n      pip.textContent = String(q.id);\n      wp.appendChild(pip); cont.appendChild(wp);\n    }\n  }\n\n  function build() {\n    var cont, i, q, opts, card, top, nd, meta, tagRow, tg, dl,\n        st, rule, od, ed, lb, tx, ep, epl, ept, j, oe, ls, ts;\n    cont = gid('cases');\n    if (!cont) return;\n    cont.innerHTML = '';\n    answers = {}; answered = 0; shuffled = {}; done = false;\n    if (gid('score')) gid('score').style.display = 'none';\n    buildPips();\n    for (i = 0; i < QS.length; i++) {\n      q    = QS[i];\n      opts = shuffleArr(q.opts);\n      shuffled[q.id] = opts;\n\n      card = document.createElement('div'); card.className = 'mr-case';\n      top  = document.createElement('div'); top.className  = 'mr-case-top';\n      nd   = document.createElement('div'); nd.className   = 'mr-num';\n      nd.textContent = q.id < 10 ? '0' + q.id : String(q.id);\n      meta = document.createElement('div'); meta.className = 'mr-meta';\n\n      tagRow = document.createElement('div'); tagRow.className = 'mr-tag-row';\n      tg = document.createElement('div'); tg.className = 'mr-tag'; tg.innerHTML = q.tag;\n      dl = document.createElement('div'); dl.className = 'mr-diff'; dl.textContent = q.diff;\n      tagRow.appendChild(tg); tagRow.appendChild(dl);\n\n      st = document.createElement('div'); st.className = 'mr-stem'; st.innerHTML = q.stem;\n      meta.appendChild(tagRow); meta.appendChild(st);\n      top.appendChild(nd); top.appendChild(meta);\n      card.appendChild(top);\n\n      rule = document.createElement('div'); rule.className = 'mr-rule';\n      card.appendChild(rule);\n\n      od = document.createElement('div'); od.className = 'mr-opts';\n      for (j = 0; j < opts.length; j++) {\n        oe = document.createElement('div'); oe.className = 'mr-opt';\n        oe.id = NS + '-o' + q.id + '-' + j;\n        oe.setAttribute('role', 'button'); oe.setAttribute('tabindex', '0');\n        ls = document.createElement('span'); ls.className = 'mr-ltr'; ls.textContent = LTRS[j];\n        ts = document.createElement('span'); ts.className = 'mr-opt-text'; ts.innerHTML = opts[j];\n        oe.appendChild(ls); oe.appendChild(ts); od.appendChild(oe);\n        (function (qid, oi) {\n          oe.addEventListener('click', function () { pick(qid, oi); });\n        }(q.id, j));\n      }\n      card.appendChild(od);\n\n      ed  = document.createElement('div'); ed.className = 'mr-exp'; ed.id = NS + '-exp' + q.id;\n      lb  = document.createElement('div'); lb.className = 'mr-exp-lbl'; lb.textContent = 'Debrief';\n      tx  = document.createElement('div'); tx.className = 'mr-exp-text'; tx.innerHTML = q.exp;\n      ed.appendChild(lb); ed.appendChild(tx);\n\n      if (q.extra) {\n        ep  = document.createElement('div'); ep.className = 'mr-exp-extra';\n        epl = document.createElement('span'); epl.className = 'mr-exp-extra-lbl'; epl.textContent = 'Extra Points';\n        ept = document.createElement('div'); ept.innerHTML = q.extra;\n        ep.appendChild(epl); ep.appendChild(ept);\n        ed.appendChild(ep);\n      }\n\n      card.appendChild(ed);\n      cont.appendChild(card);\n    }\n  }\n\n  function pick(qid, oi) {\n    var q, opts, i, el, ok;\n    if (answers[qid] !== undefined || done) return;\n    q = null;\n    for (i = 0; i < QS.length; i++) { if (QS[i].id === qid) { q = QS[i]; break; } }\n    if (!q) return;\n    opts = shuffled[qid];\n    ok   = (opts[oi] === q.correct);\n    answers[qid] = ok ? 'c' : 'w';\n    answered++;\n    for (i = 0; i < opts.length; i++) {\n      el = byId(NS + '-o' + qid + '-' + i);\n      if (!el) continue;\n      el.className = opts[i] === q.correct ? 'mr-opt correct locked'\n                   : i === oi              ? 'mr-opt wrong locked'\n                                           : 'mr-opt dimmed locked';\n    }\n    var ex = byId(NS + '-exp' + qid); if (ex) ex.style.display = 'block';\n    var pp = byId(NS + '-pip' + qid); if (pp) pp.className = 'mr-pip ' + (ok ? 'correct' : 'wrong');\n    if (qid > 1) { var pl = gid('pl' + qid); if (pl) pl.className = 'mr-pip-line done'; }\n  }\n\n  function showScore() {\n    var c, w, s, net, pct, disp, vlist, vi, sc;\n    if (done) return;\n    done = true;\n    c   = countVal('c'); w = countVal('w'); s = TOTAL - answered;\n    net  = c * 4 - w;\n    pct  = Math.max(0, Math.round((net \/ MAX) * 100));\n    disp = Math.min(100, Math.max(0, pct));\n    var rg = gid('ring');\n    if (rg) rg.style.background = 'conic-gradient(#1A6B5A ' + disp + '%, #D8E8E5 0%)';\n    var pe = gid('pct'); if (pe) pe.textContent = pct + '%';\n    var ne = gid('net'); if (ne) ne.textContent = 'Net Score: ' + net + ' \/ ' + MAX;\n    vlist = [\n      [5, 'Flawless. The liver has no secrets left for you.'],\n      [4, 'Strong round \\u2014 one complication or mechanism worth a second read.'],\n      [3, 'Solid base \\u2014 the Extra Points sections carry the clinical edge.'],\n      [2, 'Halfway there \\u2014 portal hypertension and Wilson\\'s are the places to focus.'],\n      [0, 'Liver diseases reward methodical revision. Everything you need is in the debrief.']\n    ];\n    var ve = gid('verdict');\n    if (ve) {\n      ve.textContent = vlist[4][1];\n      for (vi = 0; vi < vlist.length; vi++) {\n        if (c >= vlist[vi][0]) { ve.textContent = vlist[vi][1]; break; }\n      }\n    }\n    var cc = gid('ct-c'); if (cc) cc.textContent = '\\u2705 ' + c + ' Correct';\n    var cw = gid('ct-w'); if (cw) cw.textContent = '\\u274C ' + w + ' Wrong';\n    var cs = gid('ct-s'); if (cs) cs.textContent = '\\u23ED ' + s + ' Skipped';\n    sc = gid('score');\n    if (sc) { sc.style.display = 'block'; sc.scrollIntoView({ behavior: 'smooth', block: 'center' }); }\n  }\n\n  function initObserver() {\n    var sn = gid('sentinel'), bar = gid('progress');\n    if (!sn || !bar || !window.IntersectionObserver) return;\n    new IntersectionObserver(function (en) {\n      bar.className = en[0].isIntersecting ? 'mr-progress' : 'mr-progress visible';\n    }, { threshold: 0 }).observe(sn);\n  }\n\n  function init() {\n    var sb = gid('submit'), rb = gid('retry');\n    if (!sb || !rb) return;\n    sb.addEventListener('click', showScore);\n    rb.addEventListener('click', function () { build(); window.scrollTo(0, 0); });\n    initObserver();\n    build();\n  }\n\n  function tryInit(n) {\n    if (document.getElementById('git04-cases')) {\n      init();\n    } else if (n < 40) {\n      setTimeout(function () { tryInit(n + 1); }, 50);\n    }\n  }\n\n  tryInit(0);\n\n}());\n<\/script>\n\n\n","protected":false},"excerpt":{"rendered":"<p>Morning Rounds &middot; GIT Series Liver DiseasesGastroenterology Five high-yield clinical cases &middot; +4 \/ &minus;1 scoring &middot; NEET-PG and UPSC CMS 5 Cases +4 \/ &minus;1 scoring Options reshuffled Submit for Debrief Round Complete 0% net Your Debrief &#8635; New Round<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"","neve_meta_content_width":0,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","footnotes":""},"categories":[18,76,74,24],"tags":[],"class_list":["post-36920","post","type-post","status-publish","format-standard","hentry","category-cms","category-git","category-morning-rounds","category-neet-pg"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Liver Diseases - atsixty<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/atsixty.com\/index.php\/cms\/liver-diseases\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Liver Diseases - atsixty\" \/>\n<meta property=\"og:description\" content=\"Morning Rounds &middot; GIT Series Liver DiseasesGastroenterology Five high-yield clinical cases &middot; +4 \/ &minus;1 scoring &middot; NEET-PG and UPSC CMS 5 Cases +4 \/ &minus;1 scoring Options reshuffled Submit for Debrief Round Complete 0% net Your Debrief &#8635; New Round\" \/>\n<meta property=\"og:url\" content=\"https:\/\/atsixty.com\/index.php\/cms\/liver-diseases\/\" \/>\n<meta property=\"og:site_name\" content=\"atsixty\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-03T14:27:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-03T14:28:11+00:00\" \/>\n<meta name=\"author\" content=\"Avi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Avi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/cms\\\/liver-diseases\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/cms\\\/liver-diseases\\\/\"},\"author\":{\"name\":\"Avi\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/#\\\/schema\\\/person\\\/cf65e7ac7d8226d95c0bdf1036f7951d\"},\"headline\":\"Liver Diseases\",\"datePublished\":\"2026-06-03T14:27:32+00:00\",\"dateModified\":\"2026-06-03T14:28:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/cms\\\/liver-diseases\\\/\"},\"wordCount\":37,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/#\\\/schema\\\/person\\\/cf65e7ac7d8226d95c0bdf1036f7951d\"},\"articleSection\":[\"CMS\",\"GIT\",\"Morning Rounds\",\"NEET PG\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/atsixty.com\\\/index.php\\\/cms\\\/liver-diseases\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/cms\\\/liver-diseases\\\/\",\"url\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/cms\\\/liver-diseases\\\/\",\"name\":\"Liver Diseases - atsixty\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/#website\"},\"datePublished\":\"2026-06-03T14:27:32+00:00\",\"dateModified\":\"2026-06-03T14:28:11+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/cms\\\/liver-diseases\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/atsixty.com\\\/index.php\\\/cms\\\/liver-diseases\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/cms\\\/liver-diseases\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/atsixty.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Liver Diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/#website\",\"url\":\"https:\\\/\\\/atsixty.com\\\/\",\"name\":\"At Sixty\",\"description\":\"The Option Taken\",\"publisher\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/#\\\/schema\\\/person\\\/cf65e7ac7d8226d95c0bdf1036f7951d\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/atsixty.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":[\"Person\",\"Organization\"],\"@id\":\"https:\\\/\\\/atsixty.com\\\/#\\\/schema\\\/person\\\/cf65e7ac7d8226d95c0bdf1036f7951d\",\"name\":\"Avi\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/logo-agency.png\",\"url\":\"https:\\\/\\\/atsixty.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/logo-agency.png\",\"contentUrl\":\"https:\\\/\\\/atsixty.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/logo-agency.png\",\"width\":200,\"height\":200,\"caption\":\"Avi\"},\"logo\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/logo-agency.png\"},\"sameAs\":[\"https:\\\/\\\/atsixty.com\"],\"url\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/author\\\/avinaux\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Liver Diseases - atsixty","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/atsixty.com\/index.php\/cms\/liver-diseases\/","og_locale":"en_US","og_type":"article","og_title":"Liver Diseases - atsixty","og_description":"Morning Rounds &middot; GIT Series Liver DiseasesGastroenterology Five high-yield clinical cases &middot; +4 \/ &minus;1 scoring &middot; NEET-PG and UPSC CMS 5 Cases +4 \/ &minus;1 scoring Options reshuffled Submit for Debrief Round Complete 0% net Your Debrief &#8635; New Round","og_url":"https:\/\/atsixty.com\/index.php\/cms\/liver-diseases\/","og_site_name":"atsixty","article_published_time":"2026-06-03T14:27:32+00:00","article_modified_time":"2026-06-03T14:28:11+00:00","author":"Avi","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Avi","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/atsixty.com\/index.php\/cms\/liver-diseases\/#article","isPartOf":{"@id":"https:\/\/atsixty.com\/index.php\/cms\/liver-diseases\/"},"author":{"name":"Avi","@id":"https:\/\/atsixty.com\/#\/schema\/person\/cf65e7ac7d8226d95c0bdf1036f7951d"},"headline":"Liver Diseases","datePublished":"2026-06-03T14:27:32+00:00","dateModified":"2026-06-03T14:28:11+00:00","mainEntityOfPage":{"@id":"https:\/\/atsixty.com\/index.php\/cms\/liver-diseases\/"},"wordCount":37,"commentCount":0,"publisher":{"@id":"https:\/\/atsixty.com\/#\/schema\/person\/cf65e7ac7d8226d95c0bdf1036f7951d"},"articleSection":["CMS","GIT","Morning Rounds","NEET PG"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/atsixty.com\/index.php\/cms\/liver-diseases\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/atsixty.com\/index.php\/cms\/liver-diseases\/","url":"https:\/\/atsixty.com\/index.php\/cms\/liver-diseases\/","name":"Liver Diseases - atsixty","isPartOf":{"@id":"https:\/\/atsixty.com\/#website"},"datePublished":"2026-06-03T14:27:32+00:00","dateModified":"2026-06-03T14:28:11+00:00","breadcrumb":{"@id":"https:\/\/atsixty.com\/index.php\/cms\/liver-diseases\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/atsixty.com\/index.php\/cms\/liver-diseases\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/atsixty.com\/index.php\/cms\/liver-diseases\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/atsixty.com\/"},{"@type":"ListItem","position":2,"name":"Liver Diseases"}]},{"@type":"WebSite","@id":"https:\/\/atsixty.com\/#website","url":"https:\/\/atsixty.com\/","name":"At Sixty","description":"The Option Taken","publisher":{"@id":"https:\/\/atsixty.com\/#\/schema\/person\/cf65e7ac7d8226d95c0bdf1036f7951d"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/atsixty.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":["Person","Organization"],"@id":"https:\/\/atsixty.com\/#\/schema\/person\/cf65e7ac7d8226d95c0bdf1036f7951d","name":"Avi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/atsixty.com\/wp-content\/uploads\/2025\/08\/logo-agency.png","url":"https:\/\/atsixty.com\/wp-content\/uploads\/2025\/08\/logo-agency.png","contentUrl":"https:\/\/atsixty.com\/wp-content\/uploads\/2025\/08\/logo-agency.png","width":200,"height":200,"caption":"Avi"},"logo":{"@id":"https:\/\/atsixty.com\/wp-content\/uploads\/2025\/08\/logo-agency.png"},"sameAs":["https:\/\/atsixty.com"],"url":"https:\/\/atsixty.com\/index.php\/author\/avinaux\/"}]}},"_links":{"self":[{"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/posts\/36920","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/comments?post=36920"}],"version-history":[{"count":1,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/posts\/36920\/revisions"}],"predecessor-version":[{"id":36921,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/posts\/36920\/revisions\/36921"}],"wp:attachment":[{"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/media?parent=36920"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/categories?post=36920"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/tags?post=36920"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}